Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BilT-02
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
- NCT03639935 ↗
- Completed
- University of Michigan Rogel Cancer Center
- Focused
We haven't built an HCP commentary report on BilT-02 (rucaparib and nivolumab in Biliary Tract Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BilT-02 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Biliary Tract Cancer
- Interventions
- Rucaparib; Nivolumab
- Arms
- Rucaparib and Nivolumab · Experimental
- Enrollment
- 32
- Primary outcomes
- Proportion of Patients Alive and Without Radiological or Clinical Progression at 4 Months
- Sponsor
- University of Michigan Rogel Cancer Center with Dana-Farber Cancer Institute, Vanderbilt University Medical Center
- Start
- Mar 28, 2019
- Primary completion
- Feb 7, 2023
- Results posted
- Yes
- Registry record
- NCT03639935 · updated Jun 3, 2025
Publications
linked from the registry- Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02. Clin Cancer Res. 2026 Jul 23. doi: 10.1158/1078-0432.CCR-25-1114. Online ahead of print. PubMed 42489677